Matches in SemOpenAlex for { <https://semopenalex.org/work/W2949665037> ?p ?o ?g. }
- W2949665037 endingPage "617" @default.
- W2949665037 startingPage "606" @default.
- W2949665037 abstract "Background Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown beneficial effects on renal outcomes mainly in patients with established atherosclerotic cardiovascular disease. Here we report analyses of renal outcomes with the SGLT2 inhibitor dapagliflozin in the DECLARE–TIMI 58 cardiovascular outcomes trial, which included patients with type 2 diabetes both with and without established atherosclerotic cardiovascular disease and mostly with preserved renal function. Methods In DECLARE–TIMI 58, patients with type 2 diabetes, HbA1c 6·5–12·0% (47·5–113·1 mmol/mol), with either established atherosclerotic cardiovascular disease or multiple risk factors, and creatinine clearance of at least 60 mL/min were randomly assigned (1:1) to 10 mg dapagliflozin or placebo once daily. A prespecified secondary cardiorenal composite outcome was defined as a sustained decline of at least 40% in estimated glomerular filtration rate [eGFR] to less than 60 mL/min per 1·73m2, end-stage renal disease (defined as dialysis for at least 90 days, kidney transplantation, or confirmed sustained eGFR <15mL/min per 1·73 m2), or death from renal or cardiovascular causes; a prespecified renal-specific composite outcome was the same but excluding death from cardiovascular causes. In this renal analysis, we report findings for the components of these composite outcomes, subgroup analysis of these composite outcomes, and changes in eGFR at different timepoints. DECLARE–TIMI 58 is registered with ClinicalTrials.gov, number NCT01730534. Findings The trial took place between April 25, 2013, and Sept 18, 2018; median follow-up was 4·2 years (IQR 3·9–4·4). Of the 17 160 participants who were randomly assigned, 8162 (47·6%) had an eGFR of at least 90 mL/min per 1·73 m2, 7732 (45·1%) had an eGFR of 60 to less than 90 mL/min per 1·73 m2, and 1265 (7·4%) had an eGFR of less than 60 mL/min per 1·73 m2 at baseline (one participant had missing data for eGFR); 6974 (40·6%) had established atherosclerotic cardiovascular disease and 10 186 (59·4%) had multiple risk factors. As previously reported, the cardiorenal secondary composite outcome was significantly reduced with dapagliflozin versus placebo (hazard ratio [HR] 0·76, 95% CI 0·67–0.87; p<0·0001); excluding death from cardiovascular causes, the HR for the renal-specific outcome was 0·53 (0·43–0·66; p<0·0001). We identified a 46% reduction in sustained decline in eGFR by at least 40% to less than 60 mL/min per 1·73 m2 (120 [1·4% vs 221 [2·6%]; HR 0·54 [95% CI 0·43–0·67]; p<0·0001). The risk of end-stage renal disease or renal death was lower in the dapagliflozin group than in the placebo group (11 [0·1%] vs 27 [0·3%]; HR 0·41 [95% CI 0·20–0·82]; p=0·012). Both the cardiorenal and renal-specific composite outcomes were improved with dapagliflozin versus placebo across various prespecified subgroups, including those defined by baseline eGFR (cardiorenal outcome pinteraction=0·97; renal-specific outcome pinteraction=0·87) and the presence or absence of established atherosclerotic cardiovascular disease (cardiorenal outcome pinteraction=0·67; renal-specific outcome pinteraction=0·72). 6 months after randomisation, the mean decrease in eGFR was larger in the dapagliflozin group than in the placebo group. The mean change equalised by 2 years, and at 3 and 4 years the mean decrease in eGFR was less with dapagliflozin than with placebo. Interpretation Dapagliflozin seemed to prevent and reduce progression of kidney disease compared with placebo in this large and diverse population of patients with type 2 diabetes with and without established atherosclerotic cardiovascular disease, most of whom had preserved renal function. Funding AstraZeneca. Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown beneficial effects on renal outcomes mainly in patients with established atherosclerotic cardiovascular disease. Here we report analyses of renal outcomes with the SGLT2 inhibitor dapagliflozin in the DECLARE–TIMI 58 cardiovascular outcomes trial, which included patients with type 2 diabetes both with and without established atherosclerotic cardiovascular disease and mostly with preserved renal function. In DECLARE–TIMI 58, patients with type 2 diabetes, HbA1c 6·5–12·0% (47·5–113·1 mmol/mol), with either established atherosclerotic cardiovascular disease or multiple risk factors, and creatinine clearance of at least 60 mL/min were randomly assigned (1:1) to 10 mg dapagliflozin or placebo once daily. A prespecified secondary cardiorenal composite outcome was defined as a sustained decline of at least 40% in estimated glomerular filtration rate [eGFR] to less than 60 mL/min per 1·73m2, end-stage renal disease (defined as dialysis for at least 90 days, kidney transplantation, or confirmed sustained eGFR <15mL/min per 1·73 m2), or death from renal or cardiovascular causes; a prespecified renal-specific composite outcome was the same but excluding death from cardiovascular causes. In this renal analysis, we report findings for the components of these composite outcomes, subgroup analysis of these composite outcomes, and changes in eGFR at different timepoints. DECLARE–TIMI 58 is registered with ClinicalTrials.gov, number NCT01730534. The trial took place between April 25, 2013, and Sept 18, 2018; median follow-up was 4·2 years (IQR 3·9–4·4). Of the 17 160 participants who were randomly assigned, 8162 (47·6%) had an eGFR of at least 90 mL/min per 1·73 m2, 7732 (45·1%) had an eGFR of 60 to less than 90 mL/min per 1·73 m2, and 1265 (7·4%) had an eGFR of less than 60 mL/min per 1·73 m2 at baseline (one participant had missing data for eGFR); 6974 (40·6%) had established atherosclerotic cardiovascular disease and 10 186 (59·4%) had multiple risk factors. As previously reported, the cardiorenal secondary composite outcome was significantly reduced with dapagliflozin versus placebo (hazard ratio [HR] 0·76, 95% CI 0·67–0.87; p<0·0001); excluding death from cardiovascular causes, the HR for the renal-specific outcome was 0·53 (0·43–0·66; p<0·0001). We identified a 46% reduction in sustained decline in eGFR by at least 40% to less than 60 mL/min per 1·73 m2 (120 [1·4% vs 221 [2·6%]; HR 0·54 [95% CI 0·43–0·67]; p<0·0001). The risk of end-stage renal disease or renal death was lower in the dapagliflozin group than in the placebo group (11 [0·1%] vs 27 [0·3%]; HR 0·41 [95% CI 0·20–0·82]; p=0·012). Both the cardiorenal and renal-specific composite outcomes were improved with dapagliflozin versus placebo across various prespecified subgroups, including those defined by baseline eGFR (cardiorenal outcome pinteraction=0·97; renal-specific outcome pinteraction=0·87) and the presence or absence of established atherosclerotic cardiovascular disease (cardiorenal outcome pinteraction=0·67; renal-specific outcome pinteraction=0·72). 6 months after randomisation, the mean decrease in eGFR was larger in the dapagliflozin group than in the placebo group. The mean change equalised by 2 years, and at 3 and 4 years the mean decrease in eGFR was less with dapagliflozin than with placebo. Dapagliflozin seemed to prevent and reduce progression of kidney disease compared with placebo in this large and diverse population of patients with type 2 diabetes with and without established atherosclerotic cardiovascular disease, most of whom had preserved renal function." @default.
- W2949665037 created "2019-06-27" @default.
- W2949665037 creator A5000276904 @default.
- W2949665037 creator A5007149007 @default.
- W2949665037 creator A5010571732 @default.
- W2949665037 creator A5012551917 @default.
- W2949665037 creator A5014851272 @default.
- W2949665037 creator A5017963087 @default.
- W2949665037 creator A5020677154 @default.
- W2949665037 creator A5025618359 @default.
- W2949665037 creator A5027472544 @default.
- W2949665037 creator A5030057930 @default.
- W2949665037 creator A5047195042 @default.
- W2949665037 creator A5059931457 @default.
- W2949665037 creator A5062276281 @default.
- W2949665037 creator A5063682655 @default.
- W2949665037 creator A5066064493 @default.
- W2949665037 creator A5067426250 @default.
- W2949665037 creator A5071945904 @default.
- W2949665037 creator A5080414941 @default.
- W2949665037 creator A5080475619 @default.
- W2949665037 creator A5085897222 @default.
- W2949665037 date "2019-08-01" @default.
- W2949665037 modified "2023-10-18" @default.
- W2949665037 title "Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial" @default.
- W2949665037 cites W1884587593 @default.
- W2949665037 cites W1996278628 @default.
- W2949665037 cites W1997042641 @default.
- W2949665037 cites W2107031719 @default.
- W2949665037 cites W2114598208 @default.
- W2949665037 cites W2116077357 @default.
- W2949665037 cites W2123831918 @default.
- W2949665037 cites W2133169646 @default.
- W2949665037 cites W2136160292 @default.
- W2949665037 cites W2155965977 @default.
- W2949665037 cites W2424539745 @default.
- W2949665037 cites W2492672367 @default.
- W2949665037 cites W2500767839 @default.
- W2949665037 cites W2560643142 @default.
- W2949665037 cites W2626446274 @default.
- W2949665037 cites W2730290999 @default.
- W2949665037 cites W2733849831 @default.
- W2949665037 cites W2771786039 @default.
- W2949665037 cites W2782920834 @default.
- W2949665037 cites W2790193266 @default.
- W2949665037 cites W2800723402 @default.
- W2949665037 cites W2808725516 @default.
- W2949665037 cites W2808915250 @default.
- W2949665037 cites W2809703743 @default.
- W2949665037 cites W2888252873 @default.
- W2949665037 cites W2890282628 @default.
- W2949665037 cites W2900413769 @default.
- W2949665037 cites W2939222610 @default.
- W2949665037 doi "https://doi.org/10.1016/s2213-8587(19)30180-9" @default.
- W2949665037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31196815" @default.
- W2949665037 hasPublicationYear "2019" @default.
- W2949665037 type Work @default.
- W2949665037 sameAs 2949665037 @default.
- W2949665037 citedByCount "446" @default.
- W2949665037 countsByYear W29496650372017 @default.
- W2949665037 countsByYear W29496650372019 @default.
- W2949665037 countsByYear W29496650372020 @default.
- W2949665037 countsByYear W29496650372021 @default.
- W2949665037 countsByYear W29496650372022 @default.
- W2949665037 countsByYear W29496650372023 @default.
- W2949665037 crossrefType "journal-article" @default.
- W2949665037 hasAuthorship W2949665037A5000276904 @default.
- W2949665037 hasAuthorship W2949665037A5007149007 @default.
- W2949665037 hasAuthorship W2949665037A5010571732 @default.
- W2949665037 hasAuthorship W2949665037A5012551917 @default.
- W2949665037 hasAuthorship W2949665037A5014851272 @default.
- W2949665037 hasAuthorship W2949665037A5017963087 @default.
- W2949665037 hasAuthorship W2949665037A5020677154 @default.
- W2949665037 hasAuthorship W2949665037A5025618359 @default.
- W2949665037 hasAuthorship W2949665037A5027472544 @default.
- W2949665037 hasAuthorship W2949665037A5030057930 @default.
- W2949665037 hasAuthorship W2949665037A5047195042 @default.
- W2949665037 hasAuthorship W2949665037A5059931457 @default.
- W2949665037 hasAuthorship W2949665037A5062276281 @default.
- W2949665037 hasAuthorship W2949665037A5063682655 @default.
- W2949665037 hasAuthorship W2949665037A5066064493 @default.
- W2949665037 hasAuthorship W2949665037A5067426250 @default.
- W2949665037 hasAuthorship W2949665037A5071945904 @default.
- W2949665037 hasAuthorship W2949665037A5080414941 @default.
- W2949665037 hasAuthorship W2949665037A5080475619 @default.
- W2949665037 hasAuthorship W2949665037A5085897222 @default.
- W2949665037 hasBestOaLocation W29496650372 @default.
- W2949665037 hasConcept C126322002 @default.
- W2949665037 hasConcept C134018914 @default.
- W2949665037 hasConcept C168563851 @default.
- W2949665037 hasConcept C177713679 @default.
- W2949665037 hasConcept C2777180221 @default.
- W2949665037 hasConcept C2777422806 @default.
- W2949665037 hasConcept C2777995511 @default.
- W2949665037 hasConcept C2778653478 @default.
- W2949665037 hasConcept C2779581417 @default.
- W2949665037 hasConcept C500558357 @default.
- W2949665037 hasConcept C555293320 @default.